Comparing the current results to its competitors, Aim Immunotech Inc reported Revenue increase in the 1 quarter 2026 by 37.5 % year on year. The sales growth was above Aim Immunotech Inc 's competitors' average revenue growth of 4.48 %, achieved in the same quarter.
Aim Immunotech Inc , slower than the average decrease reported by the company's competitors of -22.56 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -22.56 %
Strong sales growth of 37.5 % in Overall company contributed to Aim Immunotech Inc increase in total revenue by 37.5 % Aim Immunotech Inc improved its market share in this segment, to approximately 0 %.
November 10, 2025
In the evolving landscape of oncology and infectious disease management, AIM ImmunoTech Inc. (NYSE American: AIM) has recently captured attention by detailing significant findings from completed clinical trials. The company, primarily known for its innovative immunotherapy, Ampligen (rintatolimod), has contributed to our understanding of treatment modalities in advanced recurrent ovarian cancer while also exploring novel approaches to combat emerging infectious threats. Overview of Clinical Trials 1. Advanced Recurrent Ovarian Cancer Study: On November 7, 2025, AIM presented an abstract regarding its Phase 2 clinical trial on advanced recurrent ovarian cancer during the 40th Annual SITC Meeting. The findings...
November 19, 2024
In a significant advancement within the realm of oncology, AIM ImmunoTech Inc. (NYSE American: AIM) has announced that pivotal data concerning Ampligen (rintatolimod) an innovative therapeutic agent have been published in a prominent academic journal, the Journal for ImmunoTherapy of Cancer. This publication centers on the findings from a Phase 1 study conducted by the esteemed Roswell Park Comprehensive Cancer Center, which investigated the efficacy of Ampligen as part of a chemokine-modulating (CKM) regimen for treating early-stage triple-negative breast cancer (TNBC). Understanding the Implications of the Study Triple-negative breast cancer, known for its aggressive nature and lack of specific hormonal re...
September 19, 2024
The landscape of cancer treatment continually evolves as researchers and companies strive for improvements in efficacy and patient outcomes. Recently, AIM ImmunoTech announced encouraging preliminary data from its Phase 1b/2 study investigating the combination of Ampligen and Imfinzi for patients with late-stage pancreatic cancer. This article aims to scrutinize the implications of this study while considering the stock market performance of AIM ImmunoTech, which has not mirrored these advancements. Preliminary Study Findings AIM ImmunoTech s recent press release highlighted promising preliminary data from their ongoing clinical trial. In the first cohort of subjects, two out of three patients exhibited stab...
July 29, 2024
In a significant development for the field of oncology, AIM ImmunoTech Inc. (NYSE American: AIM) has announced the release of the latest segment of its CEO Corner, where the company’s Chief Executive Officer, Thomas Equels, elaborates on the positive findings from a Phase 1 clinical trial. This trial investigates the efficacy of an innovative chemokine modulation therapy featuring the experimental treatment Ampligen when combined with the chemotherapy drug paclitaxel for early-stage, triple-negative breast cancer (TNBC) patients. Triple-negative breast cancer, a subtype that is notoriously aggressive and challenging to treat, lacks receptors for estrogen, progesterone, and the human epidermal growth factor...
April 18, 2024
AIM ImmunoTech Inc. Highlights Unmet Need and Potential Treatment for Locally Advanced Pancreatic AdenocarcinomaOCALA, Fla., April 18, 2024 - AIM ImmunoTech Inc. (NYSE American: AIM) is a biopharmaceutical company dedicated to discovering and developing immune-enhancing therapies for various diseases. In their latest CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, sheds light on the challenges faced by patients with Locally Advanced Pancreatic Adenocarcinoma (LAPC) and presents the potential for addressing this unmet medical need.LAPC is a type of pancreatic cancer that has spread to nearby tissues and organs but has not yet metastasized to distant sites. Equels emphasizes that ...
March 25, 2024
Pancreatic cancer remains one of the most challenging and deadly forms of cancer, with limited treatment options available. However, recent groundbreaking research has shed light on the potential benefits of utilizing Ampligen, a therapeutic agent that activates Toll-like receptor 3 (TLR-3) to stimulate the immune system s response against pancreatic cancer cells. This article aims to explore the seminal study conducted by AIM ImmunoTech, as published in the Journal Clinical Cancer Research, which provides compelling evidence of Ampligen s immune-stimulatory properties and its potential role in transforming pancreatic cancer treatment strategies.TLR-3 Activation and Immune-Stimulation:Toll-like receptors are...
February 14, 2024
In a stride towards revolutionizing pancreatic cancer treatment, AIM ImmunoTech has recently administered its first subject in the Netherlands for a Phase 1b/2 study evaluating the combination of Ampligen (rintatolimod) with AstraZeneca s Imfinzi (durvalumab). This groundbreaking endeavor aims to unlock novel therapeutic possibilities to combat the grave challenges posed by pancreatic cancer. With the Phase 1b portion of the study expected to be completed within six months, the implications of this development on AIM ImmunoTech are profound.Pancreatic cancer remains a significant global health burden with limited treatment options available. However, recent advances in immunotherapy have renewed hope in the ...
January 22, 2024
AIM ImmunoTech, a biotechnology company focused on the research and development of therapeutic treatments for multiple types of cancers, recently announced a milestone in its latest clinical trial. The company has accomplished the first patient enrolment at the Erasmus Medical Center in Rotterdam, Netherlands. This marks the beginning of their Phase 1b/2 clinical study which will explore the efficacy of combining Ampligen, a novel RNA nucleic acid being developed by AIM, with Imfinzi, an AstraZeneca’s product, for the treatment of late-stage pancreatic cancer.Pancreatic cancer, a notoriously hard-to-treat malignancy, is infamous for its low survival rates which have not improved significantly over the year...
January 10, 2024
Pancreatic cancer, notorious for its aggressive nature and reduced survivorship index, has remained an area of considerable concern in the domain of clinical medicine. The medical industry has fervently been scouting for innovative and effective therapeutic interventions for this grave medical condition. One of the leading biotechnology firms, AIM ImmunoTech, recently announced an open enrollment for its Phase 1b/2 clinical study that involves Ampligen (rintatolimod), a novel immunotherapeutic agent combined with AstraZeneca s Imfinzi (durvalumab), for pancreatic cancer treatment.The study, with Erasmus Medical Center in Rotterdam, Netherlands, as the key collaborator, plans to administer the first dose to t...
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
Glaxosmithkline Plc's business model focuses on researching, developing, manufacturing, and marketing innovative healthcare products and medicines globally.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Sources:
Aim Immunotech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aim Immunotech Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
